Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
United States
City of Hope, Duarte, California Stanford, Palo Alto, California University of California, San Francisco, California Moffitt Cancer Center, Tampa, Florida Winship Cancer Institute, Emory University, Atlanta, Georgia University of Chicago Medical Center, Chicago, Illinois Indian University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana Karmanos Cancer Institute, Detroit, Michigan The John Theruer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey Icahn School of Medicine at Mount Sinai, New York, New York Montefiore Einstein Comprehensive Cancer Center, The Bronx, New York The Ohio State University, Columbus, Ohio OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania SCRI Oncology Partners, Nashville, Tennessee University of Virginia, Charlottesville, Virginia